Skip to main content

Table 1 Clinicopathologic features of ampullary adenocarcinomas

From: Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

Clinicopathologic feature

No.

Percent

Median OS (months)

Log rank P

Sex

   

0.23

 Male

35

64.8

103.8

 

 Female

19

35.2

245.2

 

Age, years

   

0.16

 Mean

64.6

 

 Median

66.5

 

 Range

34-83

 

T stagea

   

0.15

 T1

6

11.3

NA

 

 T2

17

32.1

103.8

 

 T3

21

39.6

39.7

 

 T4

9

17.0

108.1

 

N stage

   

0.034

 N0

24

44.4

113.8

 

 N1

30

55.6

41.8

 

Grade

   

0.92

 I

2

3.7

113.8

 

 II

28

51.9

63.7

 

 III

24

44.4

108.1

 

Mucinous

   

0.17

 Negative

50

92.6

108.1

 

 Positive + signet ring

4

7.4

45.6

 

Perineural invasion

   

0.70

 Negative

44

81.5

108.1

 

 Positive

10

18.5

94.8

 

Lymphovascular invasion

   

0.46

 Negative

38

70.4

113.8

 

 Positive

16

29.6

57.2

 

Perioperative treatment

   

0.94

 Neoadjuvant +/or adjuvant

25

46.3

145.9

 

 None

29

53.7

103.8

 

Adenoma precursor lesion

   

0.56

 Absent

33

61.1

113.8

 

 Present

21

38.9

63.7

 

Resection margin

   

0.006

 R0

52

96.3

108.1

 

 R1

2

3.7

18.8

 

CK7 expression

   

0.70

 Negative

12

22.2

63.7

 

 Positive

42

77.8

108.1

 

CK20 expression

   

0.97

 Negative

34

63.0

113.8

 

 Positive

20

37.0

103.8

 

CDX2 expressionb

   

0.93

 Negative

33

61.1

108.1

 

 Positive

21

38.9

103.8

 

MUC1 expressionc

   

0.28

 Negative

19

35.2

113.8

 

 Positive

35

64.8

63.72

 

Histopathologic subtyped

   

0.035

 Intestinal (plus 8 mixed histology)

28

52.0

108.1

 

 Pancreaticobiliary (plus 6 mixed histology)

26

48.0

34.6

 

Histomolecular phenotype

   

0.017

 Non-Pancreaticobiliary

40

74.1

113.8

 

 Pancreaticobiliary

14

25.9

28.0

 

92-gene Classifiere

   

0.050

 Intestinal

21

38.9

108.1

 

 Pancreaticobiliary

31

57.4

36.4

 
  1. Abbreviations: OS, overall survival
  2. aT stage, N = 53, one case was carcinoma in situ
  3. bPositive CDX2 expression was defined as modified H score > 35
  4. cPositive MUC1 expression was defined as any positive staining
  5. d P value for the predominant subtype. The predominant subtypes for the 14 samples with mixed histology are also indicated
  6. eSingle gastroesophageal and single lung adenocarcinoma predictions excluded. P < 0.05 was considered statistically significant